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Reviewer #1: The authors reported a case of meningeal melanocytic tumor (MMT),
associated with a nuchal port-wine stain, with whole exome sequencing analysis to find
similarity of gene mutational rate and spectrum of the MMT to those of uveal
melanoma (UM). Additionally, they identified several candidate driver mutations of the
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MMT.
General comment.
Although genetic similarity between MMT and UM was previously reported and,
unfortunately, it remained undetermined whether the port-wine stain was genetically
related to the MMT, newly identified candidate driver mutations of the present case
would be of interest to the reader.
Respons:
We thank the reviewer for their excellent and accurate summary of our study. We
appreciate that the molecular similarity between MMT and UM has been reported
based on specific point mutations. Herein, and for the first time, we confirm these
findings across the entire exome. We further identify two recurrent mutations in EIF1AX
and CYSLTR2 which likely represent driver mutations and we present the data for the
remaining 17 somatic protein-coding alterations detected exome-wide. Although, due
to the limited available data in this rare disease, we cannot comment on the frequency
or functional significance of the other somatic alterations, our hope is that our
publically-available data (for both tumour and germline exome sequencing) could form
part of larger future analyses in this area.
The reviewer correctly pointed out that the molecular relationship of the MMT to the
port-wine stain remained undetermined in this study. In view of the difference in timing
of appearance between these lesions (congenital port-wine stain versus MMT
presenting in the eighth decade of life) as well as the entirely different cell of origins in
these anatomically distinct locations, our biological hypothesis is that these lesions are
unlikely to be molecular related. However, due to the very small number of mutations in
the MMT and lack of DNA remaining in the port-wine stain, this would require a repeat-
biopsy of the port-wine stain to conclusively prove which we do-not feel would be in the
patients’ best clinical interests. For clarity, we have added a comment that there were
no overlapping mutations between these lesions across the sequenced chromosomal
regions, and that further research will be required to determine if there is any plausible
molecular relationship.
Specific comment.
Some of the reference number in the main text seems to be incorrect.
Respons: The reviewer correctly pointed this out and a correction in the reference
numbering in the text was made.
Reviewer #2: This study examined a case of meningeal melanocytic tumor of
intermediate malignancy and an associated port-wine stain by whole-exome and
targeted sequencing, respectively. The authors confirmed the presence of previously
reported mutations in CYSLTR2 and EIF1AX and a relatively small number of
additional novel mutations in the MMT. The mutational profile was different from
cutaneous melanoma and similar to uveal melanoma, as previously reported. The
associated port-wine stain did not harbor mutations in GNAQ, GNA11, or other
vascular tumor associated genes in the targeted sequencing.
The study is interesting and, although mostly confirmatory, provides (or potentially
could provide) some novel data. I have following comments:
1.      Except for the known mutations of uveal melanoma or MMT (CYSLTR2 and
EIF1AZ), the significance of mutations identified is quite unclear. Although the authors
showed that at least 3 of them are recurrent based on the data in other cancer types,
the recurrence itself does not prove its significance. The authors may want to use
several software-based estimation (eg, PolyPhen etc.) as to how detrimental each
mutation could be. In this regard, the title " new candidate driver mutations" appears an
overstatement, as there is no proof of driving roles of these genes in the paper.
2.      Because the MMT in this case lacked mutations in GNAQ/GNA11 or vascular-
tumor related gene, it is not so interesting to test these mutations in the associated
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
port-wine stain. It is more reasonable to know whether any of the mutations identified in
the MMT exists also in the vascular tumor.
Respons: We would like to thank the reviewer for their thorough summary and for
identifying all the salient points in this study together with the key limitations.
We thank the reviewer for their accurate comment on the three other point mutations
we described in CENPV, TSPAN18 and TNIP3. We were surprised to find that (of such
few somatic alterations in the MMT) variants at these exact nucleotide positions had
been previously reported in other cancers. Although the probability of this happening
by chance is scarce, we do agree that recurrence in itself does not fully prove
significance. Running these positions through both PolyPhen-2 and SIFT does indicate
that these mutations are probably damaging (PolyPhen-2 score 1.00, 0.927 and 1.00
and SIFT score: 0.09, 0.05 and 0 for each mutation respectively). We do agree that this
not sufficient evidence to present these as potential driver mutations and have
amended this statement significantly, highlighting that their biological significance is as
yet undetermined and will clearly require further study. We accept the comment on the
manuscript title which we have amended accordingly, we believe this accurately
summarises our key findings. Our hope is that this publically available (tumour and
normal) sequencing data could form part of larger future analyses which could better
determine the biological significance of these other mutations.
As the reviewer pointed out, it is important that we draw attention to our findings of
mutations in EIF1AX and CYSLTR2 at these nucleotide positions. These mutations
had a high variant allele frequency of 0.86 and 0.48, respectively, and have been
previously reported in MMTs as described.
The reviewer highlights an excellent point regarding the possible relation of the
variants detected in the MMT to the port-wine stain. The panel sequencing of the port-
wine stain (which preceded the whole-exome sequencing of the MMT) was focussed
around key melanoma-driver and vascular-associated genes. The genes selected for
this panel were based on our biological hypotheses at the time and in retrospect, given
the evidence gleaned from the whole-exome sequencing and recent studies showing
the absence of melanoma-drivers in these tumours, we would have been keen to
interrogate the newly-identified MMT-associated alterations in the vascular lesion. Due
to the very limited number of mutations and lack of DNA in the port-wine stain a repeat-
biopsy of the port-wine stain would be the only way of conclusively answering this
question. This is technically challenging due to the very low yield of neoplastic cells
from any such biopsy and we do not feel this would be in the patients’ clinical best
interests. Biologically, in view of the difference in timing of appearance between these
lesions (congenital port-wine stain versus MMT presented in the eighth decade) as well
as the entirely different cell of origins in these anatomically distinct locations, our
hypothesis is that these lesions are unlikely to be molecular related, however this will
require further study. For clarity, we have added a comment that there were no
overlapping mutations between these lesions across the sequenced chromosomal
regions, and that further research will be required to determine if there is any plausible
molecular relationship.
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To the Editor,   
 
Melanocytic tumours originating in the leptomeninges range from low-grade melanocytomas 
to malignant melanomas. These tumours, referred to as meningeal melanocytic tumours 
(MMT), occur at a median age of 45 years and have a predilection for the cervical/thoracic 
spine and the posterior cranial fossa [4]. MMTs are sometimes associated with melanocytic 
nevi of the skin, however, the association with vascular lesions is not well documented [4]. 
MMTs share certain mutations with uveal melanoma (UM), including hotspot mutations in 
GNAQ/GNA11 and lack BRAF mutations frequently present in cutaneous melanoma (CM) 
[84]. Herein we report the first whole exome sequencing analysis of a cervical intradural 
MMT, associated with a port-wine stain. 
 
This previously healthy 85-year-old male presented with progressive cervical pain and mild 
dysesthesia in both hands. Physical examination was unremarkable. Other than a large 
congenital nuchal port-wine stain, no other cutaneous lesions were identified (Figure 1a). 
Magnetic resonance (MR) imaging showed a homogenous enhancing intradural 
extramedullary tumour extending from C2 to C4 compressing the spinal cord (Figure 1b,c). 
Cervical laminectomy and opening of the dura revealed a dark-colored extramedullary lesion 
(Figure 1d) firmly adherent to the pia. As a result, subtotal resection was performed and 
histology revealed a melanocytic tumour of intermediate-grade malignancy (Figure 1e). DNA 
methylation profiling confirmed its primary origin in the central nervous system (ESM_1). 
The patient received no additional therapy. Follow-up at two years showed no neurological 
deficits or growth of the residual tumour. Formalin-fixed and paraffin embedded material 
from the MMT was available for whole exome sequencing. A biopsy of the port-wine stain 
underwent cancer-related and selected vascular-associated gene panel sequencing (ESM_1). 
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Whole exome sequencing of the MMT (alongside matched germline DNA) revealed only 27 
somatic mutations in protein-coding regions of the genome, of which 19 were protein-altering 
and 8 were silent (Figure 2a-b, ESM_2). This low number of mutations is in stark contrast to 
CM and may reflect the lack of UV-exposure (48% of all nucleotide changes were cytidine to 
thymidine (C>T) transitions) (Figure 2c). Comparing both the mutational rate and spectrum 
of this MMT to those of 80 primary UM [1] revealed a median correlation coefficient of 
0.973, which is significantly higher than the corresponding median correlation across 64 
primary CM (p=1.725x10-11). This further supports genetic similarities between MMTs and 
UM (although the possibility FFPE deamination should be considered) (Figure 2c, ESM_3). 
 
In keeping with a recent report by van de Nes et al [10], a hotspot mutation in CYSLTR2 
(c.386T>A, p.L129Q) was detected in the MMT. In that study, CYSLTR2 mutations were 
mutually exclusive from mutations in GNAQ/GNA11, suggesting an independent driver in 
MMTs, as was the case in our patient. We also found a mutation in EIF1AX (c.7A>G, p.K3E, 
previously reported in UM [5]), with mutations in this gene occurring in conjunction with 
CYSLTR2 in MMTs [10].  
 
Of the remaining 17 protein-altering mutations, Tthree other exact nucleotide positions were 
found to be somatically mutated in the cBio catalogue of cancer mutations [1]; in CENPV 
(c.701C>A, p.A234D), TNIP3 (c.712C>T, p.R238C) and TSPAN18 (c.158C>T, p.T53M), as 
reported in carcinomas of the breast [7], skin (squamous cell) [2] and stomach [6], 
respectively. These three mutations were predicted to be deleterious in both PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/bgi.shtml)  
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and SIFT (http://sift.jcvi.org/www/SIFT_enst_submit.html), however their recurrence and 
biological significance is as yet undetermined. Sequencing reads from all variants were 
visually inspected on the Integrative Genomics Viewer (IGV) Software [8] and mutations in 
EIF1AX and CYSLTR2 were validated by capillary sequencing (ESM_1). 
 
There is only one report of a thoracic MMT associated with a sacral port-wine stain [3]. The 
anatomical proximity of the port-wine stain to the MMT in this patient is reminiscent of 
phacomatosis pigmentovascularis (port-wine stain associated with pigmented lesions of the 
skin and eye), characterised by somatic GNAQ or GNA11 mutations as in MMTs [9]. 
However, no mutations were detected in GNAQ/GNA11 or in other vascular-associated genes 
within our panel in the port-wine stain (ESM_4). We found no shared mutations between the 
MMT and the port-wine stain across the sequenced regions and tThe biological relationship of 
the MMT to the port-wine stain in this case therefore remains unclear.   
 
Herein we provide further evidence that MMT is distinct from CM and demonstrate a similar 
mutational rate and spectrum to UM. We also identify new candidate driver mutations in 
MMTs which require further validation. 
Herein we provide further evidence that MMT is distinct from CM and for the first time, 
demonstrate molecular similarities between MMT and UM across the entire exome. We also 
identify recurrent mutations in CYSLTR2 and EIF1AX which likely represent driver 
mutations. 
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Figure legends 
 
Figure 1. Port-wine stain in the neck; 6 months postoperative (A), MR imaging, axial T1 
weighted with contrast, level C3-4; homogenous enhancing intradural extramedullary tumour 
(arrow) with spinal cord compression (B), MR imaging, sagittal T1 with contrast; tumour 
extending from C2 to C4 (C), laminectomy revealed a dark-colored solid dural lesion (40mm 
in long axis). (D), Histology; pigmented spindle cell tumour with mitotic activity (arrow) 
(scale bar 50µm) (E). 
 
Figure 2. Mutational spectrum of the index patients’ tumour, showing all variants. Only 
13/27 (48%) of all nucleotide changes were cytidine to thymidine (C>T) transitions (A). Non-
synonymous mutations identified in the MMT (B). Comparison of mutational rate across this 
MMT, primary UM (n=80) and primary CM (primary tumours only indicated) (n=64). Only 
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non-synonymous variants are shown (log10 scale). Data accession from the cBio catalogue of 
cancer mutations [1] (C). 
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